Abstract  P 1342  Poster presentation   2013 EBMT London

 Observational study on the use of Orasol oral solution for mucositis prophylaxis in patients affected by lymphoma and multiple myeloma undergoing haematopoietic stem cell transplantation (HSCT) following a melphalan containing conditioning regimen

F.Mariano ,  L.Orlando,  A. Babic

European Institute of Oncology (Milan, IT)

Background: Melphalan is a chemotherapeutic drug which wil likely damage oral mucosa; melphalan containing conditioning regimens are usually administered in patients affected by lymphoma and multiple myeloma (Melphalan HD, FEAM) .  One of the most common complication of HSC transplant is  oral mucosites  (MCO)  which can cause pain, negatively affect nutrition, communication, deglutition, all symptoms that can   prolong hospitalization.   In our unit we usually use Benzidamine oral solution for mocositis prophylaxis. In case of intolerance ,we use bicarbonate+ lidocaine instead. 

Orasol is a nutrition supplement vegetal based made of Ialuronic Acid and Tabebuia Avellanedae, with antinflammatory, analgesic and antifungal activity.  The solution does not contain alcool and can be swallowed, allowing patient compliance with activity on esophageal mucosa too.

Aims: Evaluating Orasol efficacy in MCO prophylaxis in patients undergoing autologous HSCT following Melphalan containing conditioning regimen.

Methods: When patients were admitted to the hospital we illustrated Orasol characteristics and administration modalities (3 mouth washes/die: keep the solution in the mouth for some minutes and swallow the liquid)   To collect daily data we used the “evaluation  MCO” datasheet, now in use in our Unit.  At the end of the treatment or when changing the oral solution, patients were given the product satisfaction questionnaire.

Results: We collected data from 20 patients: 16/20 (6 MM,1 lymphoblastic lymphoma, 4 HD, 4 LNH and 1WD)  using Orasol concluded the treatment with Orasol (80%)   When admitted 8 patients had a G0-G1 mucositis.  At discharge, 16 patients had a G0 mucositis  Four patients interrupted the treatment with Orasol  because they did not like the taste and were put on Benzidamine oral solution and Bicarbonate+lidocaine.

Conclusions:  Orasol  has shown efficacy in mucositis prophylaxis in patients affected by lymphoma and multiple myeloma undergoing autologous HSCT with a melphalan containing regimen. Compared to Benzidamine solution ,Orasol is more versatile because does not contain alcool and can be swallowed.

 In allegato presentazione orale EBMT